- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05868499
Rollover Study From EXG-US-01
May 18, 2023 updated by: Elixirgen Therapeutics, Inc.
Long Term Follow-up Study in Patients With Telomere Biology Disorders With Bone Marrow Failure Who Completed Study EXG-US-01
This is a long-term rollover follow-up study for Phase I/II study (Protocol EXG-US-01).
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
Patients who received EXG34217 treatment and had at least one follow-up visit (Month 1, 3, 6, or 12) in Study EXG-US-01 will be eligible for this rollover study.
Patient will sign a consent form prior to any study related procedure.
This study is to add additional follow-up assessments up to 6 years after EXG34217 treatment.
This study does not have additional intervention.
Additional visits will be every 6 months in the first 3 years and once a year for two years.
Study Type
Interventional
Enrollment (Anticipated)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Minako Koga
- Phone Number: 2026156004
- Email: mkoga@kmphc.com
Study Contact Backup
- Name: Martine A Francis
- Phone Number: 13013438894
- Email: martine@mafinc.com
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Signed an Institutional Review Board (IRB) approved informed consent document indicating that they understand the purpose of, and procedures required by the study and are willing to participate in the study and comply with all study procedures and restrictions. Informed consent must be obtained from the subject prior to initiating procedures.
- Have completed the 12-month visit of Study EXG-US-01.
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EXG34217
single autologous CD34+ cells contacted ex vivo with EXG-001
|
Single infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events -Safety by Incidence of Treatment-Emergent
Time Frame: Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.03.
Incidence and nature of adverse events, vital signs, weight.
|
Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
|
umber of participants with a change in in physical examination
Time Frame: Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
|
Physical examination changes General appearance ,Head, eyes, ears, nose, and throat, Respiratory, Cardiovascular, Musculoskeletal, Abdomen, Neurologic, Extremities, Dermatologic, Lymphatic)
|
Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
|
Number of participants with a change in Electrocardiography (ECG)
Time Frame: Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
|
ECG (standard digital 12-lead in singlicate)
|
Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
|
Number of participants with a change in clinical laboratory evaluations
Time Frame: Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
|
Changes in clinical laboratory evaluations (Hematology, Blood chemistry, Coagulation, and Urinalysis)
|
Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
|
Number of participants with a change of Immunogenicity
Time Frame: Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
|
Change in Antibody against virus vector and transgene
|
Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with a change in telomere length
Time Frame: Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
|
Change in telomere length in any peripheral blood cells
|
Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
|
Number of participants with improvement of blood counts.
Time Frame: Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
|
Blood counts: neutrophils,platelets, or hemoglobin
|
Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kasiani Myers, MD, Cincinnati Children Hospital Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
July 1, 2023
Primary Completion (Anticipated)
January 30, 2027
Study Completion (Anticipated)
January 30, 2027
Study Registration Dates
First Submitted
May 8, 2023
First Submitted That Met QC Criteria
May 18, 2023
First Posted (Actual)
May 22, 2023
Study Record Updates
Last Update Posted (Actual)
May 22, 2023
Last Update Submitted That Met QC Criteria
May 18, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EXG-US-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Telomere Biology Disorders With Bone Marrow Failure
-
Elixirgen Therapeutics, Inc.RecruitingBone Marrow Failure | Telomere ShorteningUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingSevere Aplastic Anemia | Telomere Biology Disorders | Inherited Bone Marrow Failure SyndromesUnited States
-
National Cancer Institute (NCI)CompletedDyskeratosis Congenita | Telomere Biology DisordersUnited States
-
University of Sao PauloConselho Nacional de Desenvolvimento Científico e TecnológicoCompletedIdiopathic Pulmonary Fibrosis | Aplastic Anemia | Bone Marrow Failure Syndromes | Telomere ShorteningBrazil
-
National Cancer Institute (NCI)RecruitingInherited Bone Marrow Failure Syndrome | Familial Platelet Disorder With Predisposition to Myeloid MalignanciesUnited States
-
The University of QueenslandRecruitingPulmonary Fibrosis | Dyskeratosis Congenita | Telomere Shortening | Telomere DiseaseAustralia
-
University of CalgaryUnknownBone Marrow Failure Syndrome
-
Cellenkos, Inc.Active, not recruitingBone Marrow DiseaseUnited States
-
Children's Hospital of PhiladelphiaAvailableLeukemia | Immunodeficiencies | Bone Marrow Failure SyndromeUnited States
-
St. Jude Children's Research HospitalActive, not recruitingAplastic Anemia | Bone Marrow Failure SyndromeUnited States
Clinical Trials on EXG34217
-
Elixirgen Therapeutics, Inc.RecruitingBone Marrow Failure | Telomere ShorteningUnited States